[Novel anti-CML agents beyond imatinib].
作者信息
Kimura Shinya
出版信息
Rinsho Ketsueki. 2007 Jun;48(6):475-84.
PMID:17633095
Abstract
摘要
相似文献
1
[Novel anti-CML agents beyond imatinib].[除伊马替尼之外的新型抗慢性粒细胞白血病药物]
Rinsho Ketsueki. 2007 Jun;48(6):475-84.
2
Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.开发用于治疗伊马替尼耐药慢性粒细胞白血病患者的新型酪氨酸激酶抑制剂。
Rinsho Ketsueki. 2009 Jul;50(7):547-55.
3
[Development of ABL tyrosine kinase inhibitors].
Rinsho Ketsueki. 2010 Aug;51(8):597-604.
4
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.慢性粒细胞白血病治疗中的新型药物：酪氨酸激酶抑制剂及其他。
Hematology Am Soc Hematol Educ Program. 2008:427-35. doi: 10.1182/asheducation-2008.1.427.
5
Kinase inhibitors in chronic myelogenous leukemia.慢性粒细胞白血病中的激酶抑制剂
Clin Adv Hematol Oncol. 2006 May;4(5):365-74.
6
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.慢性粒细胞白血病的新型靶向治疗：克服伊马替尼耐药性的机遇
Semin Hematol. 2007 Jan;44(1 Suppl 1):S25-31. doi: 10.1053/j.seminhematol.2006.12.003.
7
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.博舒替尼、达沙替尼和尼罗替尼对18种伊马替尼耐药的BCR/ABL突变体的活性。
J Clin Oncol. 2009 Jan 20;27(3):469-71. doi: 10.1200/JCO.2008.19.8853. Epub 2008 Dec 15.
8
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.激酶抑制剂博舒替尼及其与 Abl 酪氨酸激酶结构域结合的异构体的结构和光谱分析。
PLoS One. 2012;7(4):e29828. doi: 10.1371/journal.pone.0029828. Epub 2012 Apr 6.
9
New and established tyrosine kinase inhibitors for chronic myeloid leukemia.用于慢性粒细胞白血病的新型及已上市的酪氨酸激酶抑制剂。
Drugs Today (Barc). 2012 Sep;48(9):601-13. doi: 10.1358/dot.2012.48.9.1869590.
10
Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.治疗相关因素、患者相关因素和疾病相关因素与酪氨酸激酶抑制剂治疗慢性髓系白血病的不良反应的发生有关。
Pharmacotherapy. 2013 Aug;33(8):868-81. doi: 10.1002/phar.1266. Epub 2013 Apr 3.
Zotero 插件